Ansa Biotechnologies
Ansa Biotechnologies is a provider of DNA synthesis technology using enzymatic methods. The company's technology is based on polymerase-nucleotide conjugates that can extend a DNA molecule by one building block at a time, offering a next-generation alternative to traditional chemical DNA synthesis. This enzymatic approach enables longer, more accurate DNA sequences with reduced environmental impact. Ansa's…
Funding snapshot
About
Ansa Biotechnologies is a provider of DNA synthesis technology using enzymatic methods. The company's technology is based on polymerase-nucleotide conjugates that can extend a DNA molecule by one building block at a time, offering a next-generation alternative to traditional chemical DNA synthesis. This enzymatic approach enables longer, more accurate DNA sequences with reduced environmental impact. Ansa's technology serves applications in synthetic biology, drug discovery, diagnostics, and genetic engineering. Founded in 2017 and headquartered in Berkeley, California, Ansa Biotechnologies has raised approximately $176.7 million at the Series B stage from investors including Northpond Ventures, RA Capital Management, Mubadala, Fifty Years, Horizons Ventures, Altitude Life Science Ventures, PEAK6, Carbon/Silicon, Codon Capital, Cerberus Capital Management, America's Seed Fund, and Humboldt Fund. The company employs 76 people.
Business model
Genomics > Enabling Technologies > Instrument Systems > Nucleic Acid Synthesis,
Life Sciences Platforms and Tools > Instruments > Genomics > Nucleic Acid Synthesis
Team background
College Wise > Massachusetts Institute of Technology, University of California (Berkeley)
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.
Raising like Ansa Biotechnologies?
Analyze your pitch deck before your next raise.
Analyze My Deck →